Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ondansetron for Prevention of Post-ERCP Pancreatitis
NCT06861010Phase 3Recruiting
- Sponsor
- Tanta University
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ondansetron in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP), sponsored by Tanta University. Started Mar 2025; status: recruiting.
02
Drugs
ondansetron
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on NCT06861010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06861010.